A Phase 1, Randomized, Placebo-controlled, Investigator and Participant Blinded, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3985297 in Healthy Participants
Latest Information Update: 02 Mar 2025
At a glance
- Drugs LY 3985297 (Primary) ; LY 3985297 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly and Company
- 06 Jan 2025 Planned End Date changed from 1 Jul 2025 to 1 Sep 2025.
- 06 Jan 2025 Planned primary completion date changed from 1 Jul 2025 to 1 Sep 2025.
- 25 Jun 2024 Status changed from not yet recruiting to recruiting.